Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death

Gut

Volumn 47, Issue 1, 2000, Pages 131-136

  Degos, F ^a   Christidis, C ^b   Ganne Carrie, N ^b   Farmachidi, J P ^a   Degott, C ^a   Guettier, C ^b   Trinchet, J C ^b   Beaugrand, M ^b   Chevret, S ^c  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Cirrhosis; Hepatitis C; Hepatocellular carcinoma; Survival

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ANTIVIRUS AGENT; BILIRUBIN;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; ESOPHAGUS VARICES; FEMALE; FRANCE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SEX RATIO;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033917644     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.1.131     Document Type: Article

References (32)

1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
2. Arista-Nasr J, Pichardo-Bahena R, Castaneda B, et al. Hepatitis C: a disease with a wide morphological spectrum? J Clin Gasiroenierol 1996;22:121-5.
3. Caselmann VH, Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol 1996;24S:61-6.
4. Di Bisceglie AM, Goodman ZD, Ishak KG, el al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepaiology 1991;14:969-74.
5. Ikeda K, Saitoh S, Koida I, et al. A multi-ariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepaiology 1993;18:47-53.
6. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, nori-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatalogy 1990;12:671-5.
7. Koretz RL, Abbey H, Coleman E, et ai. Non-A, non-B posttransfusion hepatitis. Ann Intern Med 1993;119:110-15.
8. Naoumov NV, Chokshi S, Metivier E, et al. Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. J Hepatol 1997;27:331-6.
9. Roudot-Thoraval F, Bastié A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepaiology 1997;26:485-90.
10. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. A' EnglJ Med 1992;327:1906-11.
11. Simonetti RG, Camma C, Fiorello F, el al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992;116:97-102.
12. Takano S, Yokosuka O, Imazeki F, al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepaiology 1995;21:650-55.
13. Tong AiJ, El-Farra NS, Reikes A, et aï. Clinical outcomes after transfusion-associated hepatitis C. A' Engl J Med 1995;332:1463-6.
14. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. A7 Engl J Med 1993;328:1791-801.
15. Terrault NA, Wright TL. Hepatitis C virus in the setting of transplantation. Semin Liver Dis 1995; 15:92-100.
16. Serfaty L, Aumaître H, Chazouillières O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepaiology 1998;27:1435-40.
17. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112: 463-72.
18. Imai Y, Kawata S, Tamura S, et al. Relation of Interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Mcd 1998;129:94-9.
19. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-102.
20. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCVrelated liver cirrhosis. J Hepatol 1996;24:141-7.
21. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis, Lanc1995;346:1051-5.
22. Andersen PK. Multistate models in survival analysis: a study of nephropathy and mortality in diabetes. StatMed 1988;7: 661-70.
23. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;l:431-5.
24. Andersen PK, Borgan 0. Counting process models for life history data: a review (with discussion). ScandJ Stat 1985; 12:97-158.
25. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of large cell dysplasia in western patients with cirrhosis. Hepatology 1996;23:1112-18.
26. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroentcrology 1995;10S: 812-17.
27. Ganne-Carrie N, Chastang C, Pateron D, el ai. Does a previous infection by hepatitis B virus play a role in the occurrence of hepatocellular carcinoma in western patients with cirrhosis mainly due to alcohol or hepatitis C virus? Hepatology 1996;24S:1374A.
28. International Interferon Alpha Hepatocellular Study Group. Effect of interferon alfa on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-9.
29. Shiratori Y, Yokosuka R, Ihori M, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:1573-80.
30. Valla DC, Chevallier M, Marcellin P, 'et al. Treatment of hepatitis C virus related cirrhosis: a randomized controlled trial of interferon alfa2b versus no treatment. Hepatology 1999;29:1870-5.
31. Fattovich G, Giustiria G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
32. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.